AVX 001

Drug Profile

AVX 001

Alternative Names: AKH-217; AVX-001

Latest Information Update: 29 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Avexxin
  • Class Antipsoriatics; Small molecules
  • Mechanism of Action Immunomodulators; Phospholipase A2 modulators; Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Atopic dermatitis; Plaque psoriasis

Most Recent Events

  • 29 Dec 2016 Avexxin completes a phase II trial in Atopic dermatitis (In adolescents, In adults, In the elderly) in Denmark (Topical) (EudraCT2016-003013-96)
  • 28 Sep 2016 Phase-II clinical trials in Atopic dermatitis (In adolescents, In adults, In the elderly) in Denmark (Topical) (EudraCT2016-003013-96)
  • 02 Jul 2015 Avexxin completes a phase-I/II trial in Psoriasis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top